Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis

Journal of Rheumatology

Volumn 35, Issue 3, 2008, Pages 421-424

  Cansu, Döndü Ü ^a,b   Kaļifoǧlu, Timuçin ^a,b   Korkmaz, Cengiz ^a,b  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b Department of Rheumatology ^*  (Turkey)

Author keywords

Anti tumor necrosis factor ; Etanercept; Hepatitis B; Hepatitis C; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RIBAVIRIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADD ON THERAPY; ADULT; ANKYLOSING SPONDYLITIS; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; PRIORITY JOURNAL; PROPHYLAXIS; RHEUMATOID ARTHRITIS; SHORT COURSE THERAPY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIRUS LATENCY;

EID: 40649094547     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005;64:788-9.
2. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7.
3. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic disease in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9.
4. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-a therapy: Guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366-71.
5. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82.
6. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51:800-4.
7. Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepatol 2003;10:285-93.
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatid arthritis. Arthritis Rheum 1988;31:315-24.
9. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 1984;27:361-7.
10. Knodell RG, Ihsak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
11. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9.
12. Neuman MG, Benhamou JP, Ibrahim A, et al. Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy. Rom J Gastroenterol 2002;11:97-103.
13. Neuman MG, Benhamou JP, Malkiewicz IM, et al. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochemist 2001;34:173-82.
14. Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF-alpha receptors. Ann Rheum Dis 2001;60:133-9.
15. Bellisai F, Giannitti C, Donvito A, Galeazzi M. Combination therapy with cyclosporine A and anti-TNF-a agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 2007;26:1127-9.
16. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology Oxford 2006;45:1294-7.
17. Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005;52:2519-20.
18. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003;30:1624-5.
19. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5.
20. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-77.
21. Duvoux C, Pawlotsky JM, Cherqui D, et al. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. A useful test for diagnosis of hepatitis C virus reinfection. Transplantation 1995;60:457-61.
22. Arase Y, Ikeda K, Chayama K, et al. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol 2000;35:221-5.
23. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.